- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02625909
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)
A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
SOF/VEL is a new treatment for hepatitis C called direct acting antiviral which targets the hepatitis C virus replication cycle and has been shown in phase II studies in chronic HCV to be highly effective (SVR12 >95%) when given for 12 weeks.
Data has shown that treatment can be shortened when treating recently acquired HCV with interferon containing treatments. It is not known whether treatment with SOF/VEL can be shortened.
This study aims to find out if treatment for 6 weeks with open-label SOF/VEL is equivalent to treatment for 12 weeks with SOF/VEL in participants with recently acquired hepatitis C infection. The project is a randomised study where both participants and investigators would not find out the treatment duration of the participants until week 6 of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Globally, 3-4 million new HCV infections are estimated to occur annually. People who inject drugs (PWID) represent one of the groups at highest risk of transmitting and acquiring infection with the majority of new (60%) and existing (80%) infections in developed countries occur in this population with HCV antibody prevalence estimated at 67% (60-80%). HIV-positive men-who-have-sex-with-men (MSM) are another high risk group for HCV acquisition.
Direct acting antivirals (DAA) has changed the treatment landscape for individuals with chronic HCV infection with interferon-free therapy offering high effectiveness and tolerability, even in "difficult-to-treat" populations.
Given the burden of HCV-related disease among PWID and HIV-positive MSM, strategies to enhance HCV assessment, treatment and prevention in these groups are urgently needed. Much of what is known about the timing of treatment initiation, regimen choice and duration of therapy in acute HCV infection comes from small observational studies and randomized controlled (randomly assigned into one or other of the different treatment groups)trials in selected populations with limited data on treatment in PWID and HIV co-infection. With recent rapid advances in HCV treatments, management strategies for acute HCV will evolve rapidly over the next few years.
The REACT study will compare the efficacy and safety of open-label SOF/VEL administered for 6 or 12 weeks in individuals with recent HCV infection. Participants will be randomised into receiving 6 weeks or 12 weeks treatment. Both investigators and participants will be blinded to the treatment duration until week 6 of treatment. The role and activity of DAA regimens in acute HCV infection requires evaluation, with the potential to be given as highly effective, short course interferon-sparing regimens, maximising acceptability to patients, encouraging uptake of treatment, limiting further transmission and preventing progression to chronic liver disease.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- St. Vincent's Hospital
-
Sydney, New South Wales, Australia, 1340
- Kirketon Road Centre
-
Sydney, New South Wales, Australia, 2052
- The Kirby Institute, University of New South Wales Australia
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St Paul's Hospital
-
Victoria, British Columbia, Canada, V8W 1M8
- Cool Aid Community Health Centre
-
-
Ontario
-
Toronto, Ontario, Canada, ON M57 2S8
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, QC H2X 1P1
- Centre Hospitalier de l' Universite de Montreal
-
-
-
-
-
Berlin, Germany, 10243
- Praxis Dr Cordes
-
Berlin, Germany, 10439
- Zentrum für Infektiologie Berlin-Prenzlauer Berg
-
Bonn, Germany, 53105
- University Hospital of Bonn
-
Frankfurt, Germany, 60596
- Infektio-Research GmbH
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Academic Medical Centre, University of Amsterdam
-
-
-
-
-
Auckland, New Zealand, 1142
- Auckland City Hospital
-
-
-
-
-
Bern, Switzerland, 3010
- Bern University Hospital
-
Lugano, Switzerland, 6900
- Fondazione Epatocentro Ticino
-
-
Zurich
-
Zürich, Zurich, Switzerland, 8091
- University Hospital Zurich
-
-
-
-
-
London, United Kingdom, NW3 2QG
- Royal Free Hospital
-
London, United Kingdom, SW10 9NH
- Chelsea & Westminster Hospital
-
-
Brigton And Hove
-
Brighton, Brigton And Hove, United Kingdom, BN2 1ES
- Brighton & Sussex University Hospitals NHS Trust
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom, M8 5RB
- Pennine Acute Hospitals NHS Trust
-
-
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114-2621
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible to participate in this study:
- Participants have voluntarily signed the informed consent form.
- 18 years of age or older.
- Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance
- HCV genotypes 1-6.
- HBsAg negative
- Compensated liver disease (Child-Pugh A)
- Negative pregnancy test at baseline (females of childbearing potential only).
- Medically stable on the basis of physical examination, medical history and vital signs
- Adequate English to provide reliable responses to the study questionnaires
- All fertile males and females must be using effective contraception during treatment and during the 30 days after treatment end.
- Recently acquired HCV infection (estimated duration of infection ≤12 months)*
Recently acquired HCV infection as defined by:
A) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Documented anti-HCV Ab negative within the 12 months prior to anti-HCV antibody positive result
OR
B) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Acute clinical hepatitis [jaundice or alanine aminotransferase (ALT)] > 10 X ULN) within the previous 6 months prior to first positive HCV antibody or HCV RNA, with no other cause of acute hepatitis identifiable
OR
C) For cases of recent HCV reinfection the following criteria are required:
Documented prior HCV antibody positive with HCV RNA negative on at least 2 occasions 6 months apart AND new HCV RNA positive within the previous 6 months
*Estimated duration of infection based on midpoint between last antibody negative or HCV RNA and first antibody positive or HCV RNA in the case of seroconversion and 6 weeks prior to date of maximum ALT in the case of acute hepatitis.
If co-infection with HIV is documented, the subject must meet the following criteria:
- Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with cluster of differentiation 4 (CD4) T cell count >500 cells/mm3 OR
On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count >200 cells/mm3 and an undetectable plasma HIV RNA level.
Suitable ARV include:
- Tenofovir (TDF) and tenofovir alafenamide (TAF)
- Emtricitabine (FTC)
- Rilpivirine
- Dolutegravir
- Elvitegravir/cobicistat
Contraindicated ARV include:
- Efavirenz 50% reduction in velpatasvir (GS-5816) exposure
- Didanosine
- Zidovudine
- Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug interaction studies; please discuss with Study Principal Investigator.
Exclusion criteria:
Subjects who meet any of the exclusion criteria are not to be enrolled in this study.
History of any of the following:
- Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with the participant treatment, assessment or compliance with the protocol; participants currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.
- History of chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Solid organ transplant
- Malignancy within 5 years prior to screening, with exception of specific cancers that may have been cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are also excluded.
- Significant drug allergy (such as anaphylaxis or hepatotoxicity).
- Subject shows evidence of significant liver disease in addition to hepatitis C, which may include but is not limited to drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis (NASH), or primary biliary cirrhosis
- Subject has known cirrhosis
Any of the following lab parameters at screening:
- Direct bilirubin > 1.5 x ULN
- Platelets < 50,000/μL
- Creatinine clearance (CLcr) < 60 mL/min
- Haemoglobin < 11 g/dL for females ; < 12 g/dL for males
- Albumin < 30g/L
- Pregnant or nursing female.
- Use of prohibited concomitant medications as described in section 5.2 in the protocol
- Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent > 10 mg/day)
- Known hypersensitivity to velpatasvir, sofosbuvir or formulation excipients.
- Therapy with any anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of study drug.
- Any investigational drug ≤6 weeks prior to the first dose of study drug.
- Previous failure of therapy with sofosbuvir or an non-structural protein 5A (NS5A) inhibitor prior to the first dose of study drug.
- Ongoing severe psychiatric disease as judged by the treating physician.
- Frequent injecting drug use that is judged by the treating physician to compromise treatment safety.
- Inability or unwillingness to provide informed consent or abide by the requirements of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug: SOF/VEL for 6 weeks
Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
|
Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
Other Names:
|
Experimental: Drug: SOF/VEL for 12 weeks
Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
|
Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Intention-to-treat (ITT) Population
Time Frame: 12 weeks post treatment
|
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among intention-to-treat (ITT) population The ITT population included all randomized participants, with loss to follow-up deemed treatment failure.
|
12 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Modified Intention-to-treat (ITT) Population
Time Frame: 12 Weeks Post End of Treatment
|
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among modified intention-to-treat (ITT) population The modified ITT population included participants in the ITT population, but excluded those with non-virological reasons for treatment failure (including death and loss to follow-up) and reinfection.
|
12 Weeks Post End of Treatment
|
Number of Participants With Undetectable HCV RNA at End of Treatment (ETR) of SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Intention-to-treat (ITT) Population
Time Frame: End of treatment - week 6 of the shortened treatment duration arm, and week 12 of the standard treatment duration arm
|
To evaluate the proportion of participants with HCV RNA below the level of quantification at end of treatment of SOF/VEL for 6 Weeks as compared With 12 Weeks in People With Recent HCV Infection The ITT population included all randomized participants, with loss to follow-up deemed treatment failure.
|
End of treatment - week 6 of the shortened treatment duration arm, and week 12 of the standard treatment duration arm
|
Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Per Protocol (PP) Population
Time Frame: 12 weeks post treatment
|
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among Per Protocol (PP) population The per protocol population included participants who received >90% of scheduled treatment for >90% of the scheduled treatment period with follow-up virologic data at SVR12 (excluding reinfection and retreatments)
|
12 weeks post treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gail V Matthews, MbChB, PhD, The Kirby Institute, University of New South Wales Australia, Sydney, New South Wales, Australia, NSW 2052
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- HIV Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Coinfection
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Velpatasvir
Other Study ID Numbers
- VHCRP1401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on SOF/VEL for 6 weeks
-
Jordan Miller, Graduate StudentPhysiotherapy Foundation of CanadaCompletedResponses of People With Neck Pain Being Treated With Varying Doses of Manual Therapy: A Pilot StudyWhiplash InjuriesCanada
-
University of ChicagoRecruitingThumb OsteoarthritisUnited States
-
Gilead SciencesTerminatedHepatitis C Virus InfectionPoland, Italy, United Kingdom
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
-
Johns Hopkins UniversityCompletedHIV | Liver Disease | HCV CoinfectionUnited States
-
Gilead SciencesTerminatedHepatitis C Virus InfectionUnited States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
-
Gilead SciencesTerminatedHepatitis C Virus InfectionFrance, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis CUnited States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
-
Rambam Health Care CampusCompleted